Tyrosine News and Research RSS Feed - Tyrosine News and Research

Metastatic RCC patients may benefit from sequential TKI strategy

Metastatic RCC patients may benefit from sequential TKI strategy

For patients with metastatic renal cell carcinoma, sequential tyrosine kinase inhibitor therapy may be better option than changing to a mammalian target of rapamycin inhibitor, research suggests. [More]
Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults. [More]
Postoperative recurrent disease affects NSCLC survival after gefitinib

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report. [More]
Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco. [More]
Figitumumab development discontinued for non-adenocarcinoma NSCLC

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows. [More]
Postoperative recurrent disease affects NSCLC survival after gefitinib

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report. [More]
First-line dacomitinib may improve advanced NSCLC survival

First-line dacomitinib may improve advanced NSCLC survival

Preliminary research suggests that the second-generation tyrosine kinase inhibitor dacomitinib may improve progression-free survival in patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations. [More]
Molecular response criteria examined for CML

Molecular response criteria examined for CML

The limitations in determining molecular response in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitor therapy have been reviewed in Cancer. [More]
PD-1, PD-L1 differentially expressed in NSCLC

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates. [More]
Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

Patients with chronic myelogenous leukaemia resistant or intolerant to at least one second-generation tyrosine kinase inhibitor have a higher probability of achieving a response to the third-generation TKI ponatinib than to a further second-generation TKI, research indicates. [More]
IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL). [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]
Novel targeted therapies and treatment combinations for leukemia

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition. [More]
IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM). [More]
Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT). [More]
Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London. [More]
Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers, according to two studies led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Proceedings of the National Academy of Sciences. [More]
VE-PTP potential treatment target for retinal and choroidal vascular diseases

VE-PTP potential treatment target for retinal and choroidal vascular diseases

Targeting vascular endothelial-protein tyrosine phosphatase, which negatively regulates TIE2 activation, could help to stabilise retinal and choroidal blood vessels, researchers report. [More]
EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency. [More]
Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer Research UK to carry out a research study into the treatment of older patients with mantle cell lymphoma. [More]